Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.

Its DROPZYLLA™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. Combined with our microfluidic high throughput single cell-based functional screening system this leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

The business strategy of Memo Therapeutics is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. DROPZYLLA™ is deployed in proprietary antibody discovery programs and is made available in collaborations e.g. for screening of CAR-T; TCR-T or bi-specific antibodies.

Federal Office of Public Health (FOPH) Switzerland

Schroder Adveq

Zürcher Kantonal Bank

Verve Ventures

Redalpine

Bernina BioInvest

Jaquet Partners

Swisscanto Private Equity

Adjuvant Capital

Fresenius Medical Care

Vesalius Biocapital Partners

GF Group Holding

Memo Therapeutics AG

“AntiBKV has the potential to be a best- and first-in-class antibody for the treatment of BKV infection in kidney transplant recipients. With 50,000 kidney transplant procedures carried out in the US and Europe alone, AntiBKV addresses a large and rapidly growing market, with an estimated size well beyond USD 1 billion,” said Karsten Fischer, Chief Executive Officer of Memo Therapeutics AG.

#clinicaltrials #phase1 

https://lnkd.in/erjNXiGc

Domain Not Resolving

WPForms

Lars Spenger

Michael Sidler

Christian Schneider

Philippe Dro

Andreas Wüpper

Erik Berg

Chief Executive Officer

Frits van Alphen

Alexander Bastian

VP Commercial Strategy

Christoph Esslinger

Founder & CEO

Biotechnology Late Stage Companies With Less Than $50M in Revenue

Biotechnology Companies With More Than $1M in Revenue (Top 10K)

Europe Startups (Top 10K)

Europe, Middle East, and Africa (EMEA) Late Stage Companies With Less Than $1B in Revenue

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.

Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Series C - Memo Therapeutics

Pureos Bioventures

Series B - Memo Therapeutics

Grant - Memo Therapeutics

redalpine

Series A - Memo Therapeutics

Computer and Software Services and Scientific Services

Schlieren

Zurich

Switzerland

Europe

Memo Therapeutics

Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer

Frits van Alphen gets Memo CDO job

Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients

Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

Memo Therapeutics AG appoints Paul Carter as Chairperson

Memo Therapeutics Raises CHF 20M; Increases Series C to CHF 45M

A neutralizing antibody developed for treating BK virus infections in kidney transplant recipients, aiming to prevent organ failure and rejection.

A platform offering high-throughput and functional screening capabilities to identify potent antibodies, including ultra-rare ones, from the entire antibody repertoire.

Libraries created from clinically selected human donors for diverse antibody or target discovery projects.

A service that utilizes human sources for therapeutic antibody candidates, enhancing clinical success chances.

Utilizes immunized rabbits to generate antibodies with high affinity and diversity against human proteins, offering significant advantages over conventional technologies.

United States

North America

Estonia

India

Asia

Indonesia

HTML5

GreenSock Animation Platform

jQuery

Modernizr

Vimeo

Memo Therapeutics AG is a late-stage biotech company developing therapeutic antibodies for virus infections and cancer. Their lead program, AntiBKV, is a neutralizing antibody for treating BK virus infection in kidney transplant recipients. They also have a pipeline of antibodies targeting infectious diseases and immuno-oncology. Their technology platform enables high-throughput screening and identification of potent antibodies.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	2b8655b8
crunchbase profile	general	Nov 19, 2024 9:23 AM	0a752e35
li profile	general
translate crunchbase fundingrounds	general	Nov 19, 2024 10:11 AM	ebd9b15c
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:MEMO-THERAPEUTICS

Memo Therapeutics AG